GlassScriptPhysician profile
Ernest A Benedetto
NPI 1538100540
$8,877.08
in general payments reported to CMS, 2019-2025
30 companies · $112 in 2025
The $112 reported for 2025 was less than what a typical Mohs-Micrographic Surgery provider received nationally (typical 2025 total: $462).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,323 · 2020: $868 · 2021: $3,469 · 2022: $2,437 · 2023: $550 · 2024: $119 · 2025: $112.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $681 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $680.51 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $2,164.05 | 2019-2023 | Dupixent |
| Abbvie INC. | $1,708.59 | 2019-2023 | Rinvoq, Skyrizi |
| Janssen Biotech, INC. | $1,624.53 | 2019-2025 | Tremfya |
| Organogenesis INC. | $629.45 | 2019-2023 | Puraply |
| Incyte Corporation | $451.19 | 2021-2023 | Opzelura |
| Lilly USA, LLC | $376.36 | 2019-2022 | |
| Amgen INC. | $270.83 | 2019-2022 | |
| Ucb, INC. | $261.40 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $193.46 | 2019-2023 | |
| Genzyme Corporation | $165.75 | 2020-2022 | |
| Janssen Scientific Affairs, LLC | $123.97 | 2019 | |
| Sun Pharmaceutical Industries INC. | $116.74 | 2019-2022 | |
| Pfizer INC. | $112.62 | 2019-2023 | |
| Vyne Pharmaceuticals INC. | $104.57 | 2020-2021 | |
| Celgene Corporation | $93.72 | 2019 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merz North America, INC. | $89.19 | 2019 | |
| Leo Pharma INC. | $65.28 | 2019-2022 | |
| Biofrontera INC. | $50.60 | 2019-2021 | |
| Stemline Therapeutics INC. | $46.00 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $41.21 | 2022 | |
| Sebela Pharmaceuticals INC. | $32.17 | 2019-2023 | Naftin |
| Kerecis Limited | $27.33 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose |
| Merck Sharp & Dohme LLC | $23.99 | 2019 | |
| Sandoz INC. | $20.21 | 2019 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $14.93 | 2019 | |
| Galderma Laboratories, L.P. | $14.74 | 2019 | |
| Tactile Systems Technology INC | $14.16 | 2022 | |
| Nabriva Therapeutics, Plc | $13.83 | 2022 | |
| Mission Pharmacal Company | $13.78 | 2019 | |
| Strata Skin Sciences, INC. | $12.43 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ernest Benedetto listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.